Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMUM trial - Adjuvant Melatonin for Uveal Melanoma
2022-500307-49-00Phase 3Authorised
- Sponsor
- St. Eriks Eye Hospital
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melatonin in intraocular melanoma (2 arms), sponsored by St. Eriks Eye Hospital. Primary endpoint: Proportion of patients free from metastases at 5 years after randomization. Planned start Jun 2022; status: authorised.
02
Drugs
melatonin
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2022-500307-49-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500307-49-00.